Table 1 Clinical and laboratory characteristics of distinct cytogenetic subgroups of the studied patients with B-ALL (n = 71)
Parameter | BCR::ABL1-like n = 6 | Ph-negative other n = 33 | Ph-negative KMT2A-r n = 7 | Ph-negative TCF3::PBX1-positive n = 3 | BCR::ABL1-positive n = 22 |
|---|---|---|---|---|---|
Male; n (%) | 5 (83.3%) | 25 (75.6%) | 0 | 1 (33.3%) | 8 (36.4%) |
Age (years) | |||||
Median (range) | 31.5 (21–55) | 32 (18–69) | 35 (29–59) | 49 (24–55) | 43 (19–68) |
Immunophenotype | |||||
B-common | 5 | 23 | 0 | 1 | 21 |
Pro-B | 1 | 8 | 6 | 0 | 1 |
Pre-B | 0 | 2 | 0 | 1 | 0 |
NOS | 0 | 0 | 1 | 1 | 0 |
Aberrant expression of myeloid antigens | |||||
n (%) | 4 (66.7%) | 10 (30.3%) | 0 | 0 | 13 (59.1%) |
WBC (× 109/L) | |||||
Median (range) | 38.2 (9.4–220) | 4.7 (0.5–208) | 44.5 (4.8–259.5) | 3.35 (2.6–34) | 11.5 (0.9–131.1) |
CNSi; n (%) | 1 (9.1%) | 4 (12.1%) | 4 (57.1%) | 1 (33.3%) | 6 (27.3%) |
Response to induction | |||||
CR MRD–; n (%) | 4 (66.7%) | 18 (54.5%) | 7 (100%) | 1 (33.3%) | 12 (54.5%) |
CR MRD+; n (%) | 2 (33.3%) | 4 (12.1%) | 0 | 2 (66.7%) | 8 (36.4%) |
AlloHSCT; n (%) | 3 (50%) | 16 (48.5%) | 4 (57.1%) | 2 (66.7%) | 14 (63.65%) |
Alive; n (%) | 2 (33.3%) | 15 (45.5%) | 2 (29%) | 1 (33.3%) | 15 (68.2%) |